The addition of procarbazine, lomustine, and vincristine chemotherapy to radiation therapy (RT) was shown to lengthen both disease control and survival relative to RT alone as first-line therapy following surgery

NRG GOG-0212 indicated that treating women who received complete clinical response after first-line platinum-taxane therapy with single-agent taxane maintenance therapy only slightly improved progression-free survival—but did not improve overall survival—and lead to significant adverse events

S0931 found everolimus after surgery tended to increase recurrence-free survival time in patients with high-risk kidney cancer, although results narrowly missed reaching statistical significance

Ramucirumab plus pembrolizumab combination reduced risk of death by 31 percent compared to standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy

Affordable Care Act’s expansion of Medicaid in 2014 was followed by a significant rise in proportion of enrollees in group’s cancer trials insured by Medicaid

Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of abstracts at the annual meeting of the American Society of Clinical Oncology (ASCO)

SWOG researchers have used methylation patterns in cell-free DNA from blood samples to predict which patients with muscle-invasive bladder cancer are likely to benefit from neoadjuvant chemo and which patients can safely skip it

Adding standing physician orders to electronic record systems did not improve adherence to guidelines for prophylactic prescribing of colony-stimulating factors for febrile neutropenia and did not lower the rate of the chemotherapy side effect

A high rate of response to neoadjuvant PD-1 blockade in patients with desmoplastic melanoma suggests such therapy could reduce the extent of surgery needed on the face and neck